Clinical trial NCT06154070: An Open Label, Study of DaxibotulinumtoxinA for Migraine Prevention
Official title: A Multi-Center Unblinded Proof-of-Concept Study of DaxibotulinumtoxinA for Migraine: the 'EEG Paradigm'
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Migraine Disorders
Lead sponsor: Ki Health Partners. LLC
Sponsor class: INDUSTRY
Collaborators: name: The Los Angeles Headache Center
name: Revance Therapeutics, Inc.
First posted: 2023-12-01
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Males and Females diagnosed with Migraines between the ages of 18-75years of age who meet the eligibility criteria

Brief summary: This is a prospective, multi-center, unblinded study in patients with migraine (≥ 8 MMDs(monthly migraine days)/month) requiring preventive treatment.

Enrolled patients will receive DAXXIFY (DAX/Doxibutlinumtoxin A)administered subcutaneously per the EEG paradigm (injection pattern).

The safety and efficacy outcome measures will be assessed at selected dosing segments during the 24-week treatment phase as well as the Post Treatment (4 weeks).

There are 2 sites in the U.S. participating, where a total of 20 patients will be enrolled.

Detailed description: This is an open-label, 24-week trial of DAX for the preventive treatment of frequent migraine attacks ( ≥8 MMDs per month, currently termed high-frequency episodic migraine (HFEM), or if there are 15 or more of any headache type, CM).

The purpose of this study is to assess the safety and effectiveness of the study drug, DaxibotulinumtoxinA (DAXXIFY) over a 24-week period. DaxibotulinumtoxinA (Manufactured by Revance Therapeutics, Inc.).

The primary objective of this proof-of-concept study is to evaluate DAX effectiveness administered subcutaneously according to a novel, proprietary injection pattern ("EEG paradigm") for the preventive treatment of High Frequency Migraine/Chronic Migraine (HFEM/CM) assessed by reduction of monthly migraine days.

Evaluation of the duration of efficacy as determined by prespecified rules for retreatment (50% or increase in MMDs from nadir (look-back to weeks 4-12) beginning at week 16, along with a 1-point or more worsening in the PGIC.

* Evaluation of the safety of DAX in migraine patients
* Evaluation of time to "wear-off" (need for retreatment)
* Reduction of acute migraine medication use compared to baseline
* Patient-reported outcomes (PROs):

  * MIDAS
  * PGIC (Patient Global Impression of Change)

Eligibility criteria: Inclusion Criteria:

1. Written informed consent must be obtained from the subject in accordance with requirements of the study site's Institutional Review Board (IRB) or ethics committee, prior to initiation of any protocol-specified procedures.
2. Subject must be able to read.
3. Male or female subjects, 18 to 75 years of age inclusive.
4. Subject has at least a 1-year history of migraine (with or without aura) consistent with a diagnosis according to ICHD (International Classification of Headache Disorder), 3rd edition with the following:

   * Age of onset prior to 50 years of age
   * Migraine attacks lasting on average 4-72 hours untreated.
   * By subject report at least 8 migraine days of moderate or severe intensity per month over the previous 3 months (prior to screening)
   * Ability to distinguish migraine from non-migraine headache.
   * No more than 26 headache days of any type per month by subject report.
5. Patients with at least 8 qualified migraine days per month over the three months prior to Screening will be eligible for entry into this study (assessed by historical recall). A migraine attack must last at least 30 minutes. Any use of an acute migraine-specific medication will count as a migraine attack (day). The interval between two qualified migraine days should be at least 24 hours to be counted as distinct migraine attacks. A migraine attack that remits following treatment (or sleep) and recurs within 24 hours will be counted as one migraine attack.
6. Females should be either of non-childbearing potential by reason of surgery, radiation, menopause (one year post onset), or of childbearing potential and practicing a medically acceptable method of contraception (eg, abstinence, a barrier method plus spermicide, or IUD) for at least one month before study participation and for two months after the end of the study and have a negative urine B-hCG (Beta-human chorionic gonadotropin) at Screening. Pregnant and/or lactating females are excluded. Those women using hormonal contraceptives must also be using an additional approved method of contraception (eg, a barrier method plus spermicide, or IUD) starting with the Baseline Phase and continuing throughout the entire study period.
7. A sub-set of subjects (capped at 30% of total enrolled) on not more than 1 preventive migraine medication may remain on therapy if the dose has been stable for at least 3 months (12 weeks) prior to the observation period and is not expected to change.

   * Exceptions include onobotulinumtoxinA treatment (wash out = 4 months).
   * Patients who are able and willing to attend study visits, maintain a headache diary and otherwise comply with study related activities.
   * Patients may be naive to botulinum neuro toxin (BoNT) therapy (no minimum or cap), or have received BoNT therapy provided there is a 4-month washout period.
   * A minimum of 30% of eligible subjects will be Chronic Migraine, per ICHD-3 (The International Classification of Headache Disorder) criteria.

Exclusion Criteria:

1. Migraine patients with ≥26 headache days of any kind per month by historical report over the 3 months prior to study.
2. Patients with cluster headaches and other trigeminal autonomic cephalalgias, and other primary headaches (except tension-type headache) and secondary headaches (defined according to the Headache Classification Committee of the Internationals Headache Society (IHS), 3rd Edition, 2018),
3. Patients with a history of being non-responsive to adequate trials of more than two classes of migraine preventive treatments (e.g., beta blockers, calcium channel blockers, tricyclics, divalproex, topiramate, small or large molecule calcitonin gene-related peptide (CGRP) antagonists or onobotulinumtoxinA).
4. Patients who use the following medications as described:

   * Use of triptans, ditans or ergot-containing medications for 10 days or greater per month on average,
   * Use of NSAIDs, acetaminophen or combination analgesics (such as acetaminophen-caffeine products) 15 days or greater per month on average,
   * Use of opioids and/or butalbital containing medications for 4 days or greater per month on average,
   * Use of any two or more of the above medications (excluding opioids/butalbital) for 15 days or greater per month on average,
5. Patients with clinically significant neurological illness, other than migraine, that, in the opinion of the Investigators, may have the potential of altering pain perception or reporting.
6. Preexisting or current difficulties swallowing or breathing.
7. Known or suspected serious neuromuscular, or cardiovascular disorder (such as amyotrophic lateral sclerosis, myasthenia gravis, coronary artery disease). that in the opinion of the investigator would place the participant at increased risk of an adverse event.
8. Patients with a history of or currently having major psychiatric disorders including schizophrenia, active psychosis or bipolar disorder. Major depressive disorder and generalized anxiety disorder which, in the investigator's opinion are well-controlled, will be allowed.
9. Patients with clinically significant active hepatic disease, cardiovascular, metabolic, respiratory, renal, endocrinological (including poorly controlled diabetes mellitus), gastrointestinal diseases, and bacterial or viral infections within 30 days prior to Screening or during the Baseline Phase, that in the opinion of the investigator may interfere with subject's participation in the study or may present a risk of the subject not completing the study.
10. Patients with hematologic or solid malignancy diagnosis within 5 years prior to screening with the exception of basal cell carcinoma and squamous cell carcinoma if they have been cancer free prior to screening.
11. Body mass index of \<18 or \>35.
12. Patients who within the past 3 years have a history of or have been treated for alcohol or drug abuse.
13. Women who are unwilling or unable to use acceptable contraception during the study.
14. Women who are pregnant or breastfeeding.
15. Patients who have participated in a drug intervention study for any indication within 60 days (or 5 half-lives of the investigational drug, whichever is longer) or non-drug intervention study (such as electrical stimulation) within 30 days.

Primary outcomes:
measure: Change from baseline in monthly migraine days
timeFrame: Over weeks 9-12
Secondary outcomes:
measure: Change from baseline in monthly migraine days over weeks 5-8
timeFrame: Over weeks 5-8
measure: The percentage of patients with a ≥50% reduction from baseline in monthly migraine days over weeks 9-12.
timeFrame: Over weeks 9-12
measure: The percentage of patients with a ≥75% and 100% reduction from baseline in monthly migraine days over weeks 9-12.
timeFrame: Over weeks 9-12
measure: Change from baseline in the mean monthly migraine headache days requiring acute medication use to treat a migraine or headache across weeks 9-12.
timeFrame: Across weeks 9-12
measure: Change from baseline in the Migraine-Specific Quality-of-Life Questionnaire (MSQ) restrictive role function domain score at week 12 compared to baseline.
timeFrame: Week 12 compared to Baseline.
measure: Change from baseline in the MIDAS score at week 12, 16 and 20.
timeFrame: Baseline to week 20
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: The Los Angeles Headache Center
state: California
city: Stamford
country: United States
facility: New England Institute For Clinical Research
state: Connecticut
Study officials:
References: